This refresh
Data-driven refresh September 7, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,221 tickers); 1,740 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top 30 — quality compounders at a fair price
1. ADBE — Adobe Inc. · score 88.9
Software - Application · price $266.51 · 1Y $276.58 · 5Y $404.94 · 10Y $600.69
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 15.2x A- · PEG 0.65 A-
Why now. Adobe’s Digital Media subscription engine is the growth engine that will keep compounding earnings, anchored by 11.5% YoY revenue growth, a rock‑solid 28.7% profit margin and $10.3 B of free cash flow. Our Bull Rankings model rates the company a Quality‑Growth score of 88.9, with Quality as the strongest pillar, underscoring the durability of its cash‑generating franchise. The thesis rests on the relentless expansion of Creative Cloud and Experience Cloud among enterprises, which should keep the free‑cash‑flow engine humming for years to come.
Moat. Adobe’s moat lives in the lock‑in of its Creative Cloud suite and the integrated Experience Cloud platform, which bind photographers, video editors, marketers and developers to a single subscription ecosystem. The 62.8% ROE reflects pricing power derived from category leadership in content creation tools that competitors cannot replicate without massive R&D and ecosystem investment, creating a high switching cost for its millions of users.
Risk. The market is pricing in an implied free‑cash‑flow growth of only ~1% per year via a reverse DCF, far below the reported 11.5% revenue growth, meaning any slowdown or margin compression would expose the stock to a sharp correction. A beta of 1.42 adds volatility, and a debt‑to‑equity of 0.61 leaves limited headroom for aggressive reinvestment. A miss on subscription renewal rates would trigger the bear case, dragging the price back toward its 52‑week low of $190.12.
Horizon. 1-3 yr $276.58 (analyst consensus (n=34)) — fundamentals + valuation re-rating. 5 yr $404.94 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $600.69 if current growth sustains into durable earnings power.
2. NBIX — Neurocrine Biosciences, Inc. · score 88.4
Drug Manufacturers - Specialty & Generic · price $155.64 · 1Y $211.72 · 5Y $309.98 · 10Y $459.83
FCF $870m C+ · Rev +34.4% A · D/E 0.12 B+ · P/E 22.8x B+ · PEG 0.31 A
Why now. NBIX’s growth engine is anchored by INGREZZA, the only FDA‑approved therapy for tardive dyskinesia, which fuels a 34.4% YoY revenue surge and underpins a 20.9% profit margin. Coupled with a razor‑thin PEG of 0.31, the business compounds earnings at a pace few peers can match, making the current upside hinge on expanding the INGREZZA franchise and rolling out Orilissa and Oriahnn into broader indications.
Moat. The moat lives in INGREZZA’s unique mechanism for movement disorders, a niche with high switching costs and limited substitutes, allowing NBIX to command premium pricing that drives a near‑20% ROE despite modest leverage. This pricing power, reinforced by exclusive U.S. market exclusivity and a pipeline targeting related neurologic conditions, creates a defensible cash‑flow moat.
Risk. The stock trades at a forward P/E of 22.8, implying an 8% annual free‑cash‑flow growth that falls well short of the 34.4% revenue growth rate, suggesting the market may be over‑optimistic about sustained margin expansion; a slowdown in INGREZZA uptake or a failed trial in the pipeline would force the valuation down to the lower end of the analyst range. A breach of the 52‑week low would confirm the bear case.
Horizon. 1-3 yr $211.72 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $309.98 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $459.83 if current growth sustains into durable earnings power.
3. HRMY — Harmony Biosciences Holdings, Inc. · score 88.1
Biotechnology · price $42.25 · 1Y $47.36 · 5Y $69.35 · 10Y $102.87
FCF $355m C · Rev +24.3% A- · D/E 0.16 B+ · P/E 13.7x A- · PEG 0.49 A
Why now. Harmony’s WAKIX narcolepsy franchise is poised to dominate a $2.5B rare‑neurology market, driving a 24.3% YoY revenue growth while delivering an 18.9% profit margin and a rock‑solid PE of 13.7. Our Bull Rankings model scores HRMY an 88.1/100 quality‑growth rating, with Value as its strongest pillar, underscoring that the stock is materially under‑priced relative to its cash‑generating engine. The thesis rests on sustained expansion of WAKIX sales and pipeline upside that will keep compounding earnings.
Moat. WAKIX’s novel mechanism and FDA‑approved status give HRMY a protected niche in the narcolepsy space, creating high switching costs for patients and insurers; this IP moat fuels pricing power that translates into an ROE of 18.1% despite a modest debt‑to‑equity of 0.16. The company’s pipeline of pitolisant extensions (Phase 3 PWS, Phase 2 DM1) further entrenches its market position and limits competitive encroachment.
Risk. The Bull Rankings model flags Quality as the weakest pillar, warning that execution risk on the Phase 3 Prader‑Willi trial could stall growth, and the reverse‑DCF implies a -16% annual free‑cash‑flow growth rate baked into the current price—far below the 24.3% revenue surge, suggesting optimism may be over‑stated. A miss in any late‑stage trial would crush the valuation premium and push the stock back toward its 52‑week low of $25.52.
Horizon. 1-3 yr $47.36 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $69.35 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $102.87 if current growth sustains into durable earnings power.
4. DLO — DLocal Limited · score 87.3
Software - Infrastructure · price $15.52 · 1Y $18.70 · 5Y $27.38 · 10Y $40.61
FCF $413m C · Rev +46.6% A · D/E 0.12 B+ · P/E 22.8x B+ · PEG 0.67 A-
Why now. DLocal’s pay‑in platform for global merchants is exploding, delivering 46.6% YoY revenue growth, a rock‑solid 18% profit margin and a staggering 34.6% ROE—the exact levers that fuel our model’s 98‑point Growth pillar and lift the overall Quality‑Growth score to 87.3. At a modest PE of 22.8x and a market cap of $4.6 billion, the stock is priced for a continuation of this compounding engine, not a one‑off spike. The thesis hinges on the relentless expansion of cross‑border e‑commerce and streaming payments, where DLocal’s pay‑in suite is the default gateway.
Moat. The moat lives in DLocal’s end‑to‑end payment stack that handles international cards, local transfers, cash and hundreds of alternative methods, locking in merchants that need a single, compliant gateway for dozens of jurisdictions. This breadth creates high switching costs and a network effect: every new APM added deepens integration, while the company’s 34.6% ROE reflects pricing power derived from being the de‑facto processor for high‑growth platforms in ride‑hailing, streaming and fintech.
Risk. The biggest headwind is valuation pressure: a reverse‑DCF shows the current $15.52 price implies a negative 6% annual FCF growth over the next decade, far below the 46.6% revenue surge and the Bull Rankings model’s 98 Growth score. If the market re‑prices to reflect realistic cash‑flow growth, the PE could compress sharply, eroding upside. A sustained slowdown in cross‑border e‑commerce or a pricing war that squeezes the 18% margin would confirm the bear case.
Horizon. 1-3 yr $18.70 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $27.38 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $40.61 if current growth sustains into durable earnings power.
5. PGY — Pagaya Technologies Ltd. · score 86
Software - Infrastructure · price $22.98 · 1Y $28.91 · 5Y $42.33 · 10Y $62.79
FCF $252m C · Rev +25.6% A- · D/E 1.34 C · P/E 16.3x A- · PEG 0.04 A
Why now. Pagaya’s Decline Monetization platform is unlocking a hidden pool of credit by automatically routing rejected loan applications to its AI‑driven network, fueling a 25.6% YoY revenue surge and generating $252 m of free cash flow on a PE of 16.3x. The market still values the business at a modest $1.9 bn with a PEG of just 0.04, leaving ample upside as analysts already peg the stock at $28.91. The thesis rests on the continued scaling of this product line, which compounds cash generation at a rate far above the broader software‑infrastructure sector.
Moat. The Decline Monetization engine creates a high‑switching‑cost ecosystem: once lenders integrate the network, they rely on Pagaya’s proprietary AI to recover credit that would otherwise be lost, locking in recurring fees. This model underpins a ROE of 19.5%, reflecting pricing power derived from being the go‑to partner for sophisticated U.S. and Israeli lenders seeking to monetize declines efficiently.
Risk. Pagaya trades at a sky‑high beta of 5.37 and a debt‑to‑equity of 1.34, exposing it to market volatility and leverage risk, while the Bull Rankings model’s reverse‑DCF implies a -13% annual FCF growth—far below the 25.6% revenue growth reality, suggesting the current price may already embed overly optimistic cash‑flow assumptions. A sustained slowdown in loan‑originations or a failure to expand the network would validate this bearish view and crush the upside.
Horizon. 1-3 yr $28.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $42.33 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $62.79 if current growth sustains into durable earnings power.
6. FICO — Fair Isaac Corporation · score 85.7
Software - Application · price $932.26 · 1Y $1,464 · 5Y $2,143 · 10Y $3,179
FCF $996m C+ · Rev +24.1% A- · D/E n/a · P/E 27.0x B · PEG 0.65 A-
Why now. Software - Application · market cap $20.1b. Down 53% from 52-week high of $1998.01 — deep drawdown territory. Revenue growing +24%, comfortably above the S&P median. PEG 0.65 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Buy with a mean 1-yr target of $1,464 (implying +57% upside).
Moat. Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. FCF converts 122% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Software economics — recurring revenue, embedded customer workflows, and high gross margin all compound the moat once a base account is won. Switching costs are the lever.
Risk. Down 53% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. ROE -20% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $1,464 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $2,143 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $3,179 if current growth sustains into durable earnings power.
7. INOD — Innodata Inc. · score 85.7
Information Technology Services · price $55.66 · 1Y $122.75 · 5Y $179.72 · 10Y $266.60
FCF $184m C · Rev +39.0% A · D/E 0.02 A- · P/E 43.1x C+ · PEG 0.87 B+
Why now. The bull case hinges on Innodata’s Digital Data Solutions (DDS) platform, which is the engine behind the exploding AI‑training‑data market. The business is growing revenue at a blistering 39% YoY, converting that into a healthy 14.7% profit margin and delivering $184 m of free cash flow while maintaining a razor‑thin debt‑to‑equity of 0.02. Our model’s Growth pillar (97) tells us the compounding engine is real, and the 29.1% ROE confirms that pricing power in AI data services is already translating into outsized returns – the thesis rests on continued AI model adoption fueling DDS demand.
Moat. Innodata’s moat lives in the DDS segment’s deep integration with AI model pipelines, creating high switching costs for tech firms that need vetted, labeled data for training and safety. This stickiness, combined with a 29.1% ROE, stems from pricing power as the only provider of end‑to‑end AI data services across its global client base, a capability rivals can’t replicate quickly without massive data‑curation investments.
Risk. The bear case centers on the market pricing in unsustainable optimism: a forward P/E of 43.1 and a reverse‑DCF implied free‑cash‑flow contraction of –5% per year clash with the 39% revenue surge, suggesting the stock is overvalued. Add a beta of 2.88 and dilution from shareholder‑friendly actions, and any slowdown in AI spending or a shift to cheaper in‑house data pipelines would crush the valuation narrative. A sustained drop in revenue growth below 30% would confirm the risk.
Horizon. 1-3 yr $122.75 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $179.72 at ~26% CAGR — compounding case rests on the competitive position widening. 10 yr $266.60 if current growth sustains into durable earnings power.
8. NVDA — NVIDIA Corporation · score 85.5
Semiconductors · price $230.36 · 1Y $327.13 · 5Y $478.95 · 10Y $710.49
FCF $127.0b A · Rev +83.4% A · D/E 0.17 B+ · P/E 29.2x B · PEG 0.59 A-
Why now. NVIDIA’s AI‑centric Compute & Networking platform is cementing its role as the backbone of modern data centers, driving an eye‑popping 83.4% YoY revenue growth and a 63.7% profit margin that fuels a massive $127.0 b free‑cash‑flow haul. Our Bull Rankings model awards an 85.5/100 quality‑growth score, with Growth as the strongest pillar, underscoring that the business’s compounding engine is real‑world, not just hype. The thesis rests on the continuation of this AI data‑center surge, which the market already prices in at a 50%/yr FCF growth assumption – a bold but attainable target given today’s fundamentals.
Moat. The moat lives in NVIDIA’s proprietary AI‑accelerated GPUs and networking stack that power the world’s largest hyperscale clouds; customers face massive switching costs because workloads are tightly bound to the CUDA ecosystem. An ROE of 84.2% reflects pricing power derived from being the de‑facto standard in AI compute, a position competitors can’t replicate overnight.
Risk. The stock trades at a lofty PE of 29.2 and a beta of 2.22, meaning any slowdown in AI spend or a market pull‑back would hammer valuation fast; the 83.4% revenue surge is unlikely to sustain forever, and a dip back toward sector‑average growth would expose the premium. A breach of the 52‑week low ($164.27) or a widening of the analyst target range toward the low end would confirm the bear case.
Horizon. 1-3 yr $327.13 (analyst consensus (n=57)) — fundamentals + valuation re-rating. 5 yr $478.95 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $710.49 if current growth sustains into durable earnings power.
9. ADSK — Autodesk, Inc. · score 85.2
Software - Application · price $217.90 · 1Y $315.37 · 5Y $461.73 · 10Y $684.94
FCF $2.8b B · Rev +17.9% B+ · D/E 1.10 C · P/E 28.3x B · PEG 0.84 B+
Why now. Autodesk’s dominance in cloud‑based construction software, anchored by Revit and Autodesk Build, fuels a compounding engine as firms digitize design and field workflows. The business is delivering 17.9% YoY revenue growth, a 21.1% profit margin and a staggering 48.5% ROE, all of which underpin our Bull Rankings model’s Quality‑Growth score of 85.2 (Growth being the strongest pillar). The reverse‑DCF shows the market is pricing in only ~11% free‑cash‑flow growth, well below the actual revenue expansion, leaving ample upside for the next decade.
Moat. The integrated BIM ecosystem—Revit for design, Autodesk Build for site execution, and BIM Collaborate Pro for cloud coordination—creates high switching costs for architects, engineers and contractors who embed these tools into multi‑year project pipelines. This lock‑in, combined with subscription pricing, drives the 48.5% ROE by extracting pricing power from category leadership in the AEC (architecture‑engineering‑construction) market.
Risk. A 28.3× forward P/E and a beta of 1.31 signal that the stock trades at a premium and is sensitive to market swings, while a debt‑to‑equity of 1.1 adds balance‑sheet leverage risk. If construction spending stalls or rivals accelerate their cloud‑BIM offerings, the growth premium could evaporate, pushing the price toward the 52‑week low of $185.5 and invalidating the bull thesis.
Horizon. 1-3 yr $315.37 (analyst consensus (n=34)) — fundamentals + valuation re-rating. 5 yr $461.73 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $684.94 if current growth sustains into durable earnings power.
10. APP — AppLovin Corporation · score 84.7
Advertising Agencies · price $320.56 · 1Y $514.48 · 5Y $753.26 · 10Y $1,117
FCF $4.5b B · Rev +60.6% A · D/E 1.11 C+ · P/E 24.6x C+ · PEG 0.69 A-
Why now. AppLovin’s growth engine is anchored in MAX, its AI‑driven in‑app bidding platform that extracts premium value from publisher inventory, fueling a 60.6% YoY revenue surge and a staggering 64.6% profit margin. The business is converting that top‑line firepower into cash, delivering $4.5B of free cash flow and a PEG of 0.69, which together justify the Bull Rankings model’s 96‑point Growth pillar. The thesis rests on the persistence of AI‑optimized ad spend across mobile and connected‑TV apps, which should keep compounding cash generation for years to come.
Moat. MAX creates a real‑time auction that locks developers into a high‑margin, data‑rich ecosystem, while Adjust’s measurement suite deepens stickiness by becoming the analytics backbone for advertisers. Together they generate switching costs that rivals can’t replicate quickly, preserving pricing power and sustaining the 64.6% margin profile.
Risk. The stock trades at a lofty PE of 24.6 and a beta of 2.49, implying market expectations far above historical norms; a slowdown in AI ad spend or a misstep in MAX’s auction technology could compress margins and trigger a sell‑off. A breach of the 52‑week high ceiling at $745.61 would force a correction, and the debt‑to‑equity ratio of 1.11 adds leverage risk if cash flows falter. Confirmation of the bear case would be a quarterly miss on revenue growth or a widening of the debt ratio.
Horizon. 1-3 yr $514.48 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $753.26 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $1,117 if current growth sustains into durable earnings power.
11. DOCS — Doximity, Inc. · score 84.2
Health Information Services · price $26.35 · 1Y $29.78 · 5Y $43.60 · 10Y $64.67
FCF $306m C · Rev +11.2% B · D/E 0.01 A- · P/E 31.4x B · PEG 0.59 A-
Why now. DOCS will keep compounding because its AI‑driven Ask assistant cements physicians on the platform, driving ever‑higher engagement and ad spend. The business is already delivering 11.2% revenue growth YoY, a 25.5% profit margin, and $306 m of free‑cash‑flow—all on a near‑zero debt balance. The Bull Rankings model rates its Quality at 88, confirming that the moat is real, and the only thing that matters is that this growth engine stays locked to clinicians’ daily workflow.
Moat. The Ask AI assistant lives inside the Doximity newsfeed, giving physicians a HIPAA‑compliant, one‑click source for evidence‑based answers. With over a million U.S. doctors relying on that workflow, switching costs are high and network effects reinforce usage, while the platform’s data depth lets Doximity charge premium sponsorship rates that underpin its 25.5% margin and 18.2% ROE.
Risk. The stock trades at a lofty PE of 31.4 and a beta of 1.25, meaning any slowdown in physician‑ad spend or a shift to competing platforms would hit valuation hard. The Bull Rankings model flags Value as its weakest pillar, and the implied 9% FCF growth over ten years is already aggressive versus the 11.2% revenue pace—any miss on growth or margin compression would validate the bear case. A breach of the 52‑week low ($17.15) would be the trigger that shatters the thesis.
Horizon. 1-3 yr $29.78 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $43.60 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $64.67 if current growth sustains into durable earnings power.
12. CARG — CarGurus, Inc. · score 83.9
Internet Content & Information · price $33.74 · 1Y $41.38 · 5Y $60.59 · 10Y $89.88
FCF $315m C · Rev +13.9% B+ · D/E 0.70 B · P/E 17.4x B · PEG 0.72 A-
Why now. CarGurus’ Digital Deal platform is turning its massive dealer network into a high‑margin, repeat‑purchase engine, and that engine is revving at 13.9% revenue growth YoY, 18.2% profit margin, and a staggering 66.6% ROE. Those fundamentals sit under a modest PE of 17.4x and a sub‑1.0 PEG, meaning the market is already pricing in growth but still undervalues the cash‑generating power of its subscription‑driven dealer fees. The whole thesis hinges on the Digital Deal’s ability to lock in more online‑first transactions, compounding earnings at double‑digit rates for years to come.
Moat. The moat lives in CarGurus’ integrated marketplace that couples a huge shopper audience with a subscription‑based dealer ecosystem, creating a lock‑in where dealers pay for leads and advertisers for exposure. This network effect fuels a pricing advantage that translates into the 66.6% ROE, as each new dealer adds incremental revenue without proportionate cost, a dynamic hard for a new entrant to replicate quickly.
Risk. The bear case centers on the elevated valuation implied by the reverse‑DCF: the stock assumes a negative 5% annual free‑cash‑flow growth for a decade, far below the 13.9% revenue expansion and the 18.2% margin cushion, suggesting investors are already pricing in aggressive upside that could evaporate if dealer churn spikes or ad spend slows. A slip in the PE to double‑digit highs or a rise in debt‑to‑equity above 0.7 would confirm the over‑optimism and trigger a sell‑off.
Horizon. 1-3 yr $41.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $60.59 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $89.88 if current growth sustains into durable earnings power.
13. EXLS — ExlService Holdings, Inc. · score 82.6
Information Technology Services · price $36.63 · 1Y $44.63 · 5Y $65.34 · 10Y $96.92
FCF $297m C · Rev +13.4% B+ · D/E 0.57 C+ · P/E 23.2x B+ · PEG 0.95 B+
Why now. The bull case hinges on EXLS’s AI‑driven claims‑management platform, which is winning deep‑pocket insurers across North America and Europe. That engine fuels a 13.4% YoY revenue growth, a robust 11.7% profit margin and a stellar ROE of 32.3%, all while the stock trades at a modest PE of 23.2x versus peers. The combination of high‑margin growth and a 5% implied free‑cash‑flow expansion in our reverse‑DCF means the current price already embeds optimism, but the durable AI moat ensures the compounding engine will keep accelerating.
Moat. EXLS’s moat lives in its end‑to‑end AI analytics suite for insurance—claims processing, underwriting support and policy servicing—that locks in large insurers with high switching costs and data lock‑in. The platform’s actuarial and risk analytics deliver pricing power, driving the 32.3% ROE, while the breadth across Insurance, Healthcare and Banking spreads risk and deepens client relationships that competitors can’t replicate quickly.
Risk. The bear case focuses on the elevated valuation: a PE of 23.2x is high for a pure‑play services firm and the implied 5% FCF growth far outpaces the 13.4% revenue growth, leaving little margin for a slowdown. A modest debt‑to‑equity of 0.57 means any earnings dip could pressure leverage, and a beta of 0.81 still exposes the stock to market volatility. A miss on the consensus 1‑yr target of $44.63 would trigger a sell‑off and invalidate the growth premium.
Horizon. 1-3 yr $44.63 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $65.34 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $96.92 if current growth sustains into durable earnings power.
14. LRN — Stride, Inc. · score 82.1
Education & Training Services · price $84.68 · 1Y $97.38 · 5Y $142.58 · 10Y $211.50
FCF $433m C · Rev +4.7% C+ · D/E 0.33 A- · P/E 11.9x A · PEG 0.46 A
Why now. Stride’s end‑to‑end online platform for software engineering and healthcare upskilling is a cash‑flow machine, delivering $433 m of free cash flow on a 13.4% profit margin while trading at a rock‑bottom P/E of 11.9 and a PEG of 0.46. The combination of a 20.7% ROE and a low‑beta (0.11) balance sheet (debt‑to‑equity 0.33) lets management keep buying back shares, compounding earnings at a rate the market still underestimates. The thesis rests on the platform’s ability to keep expanding professional‑skill enrollments, which will drive free cash flow to compound year over year.
Moat. The platform’s single sign‑on, learning‑management, and state‑customized curriculum creates a high switching cost for schools and workforce partners, locking in recurring revenue. That stickiness fuels the 20.7% ROE, which stems from pricing power in the niche professional‑training market where Stride can charge premium fees for its integrated, data‑rich solution.
Risk. Revenue is only growing 4.7% YoY, far below the growth implied by the reverse‑DCF that assumes a -11% annual free‑cash‑flow decline, meaning any further slowdown would expose the stock to a valuation cliff. The Bull Rankings model flags Growth as the weakest pillar, and if the company can’t lift top‑line growth above 5%, the cheap P/E becomes a red flag and the buyback engine stalls. A sustained miss on the 4.7% growth rate would confirm the bear case.
Horizon. 1-3 yr $97.38 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $142.58 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $211.50 if current growth sustains into durable earnings power.
15. ADMA — ADMA Biologics, Inc. · score 81.8
Biotechnology · price $9.62 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $116m C · Rev +8.0% B · D/E 1.11 C · P/E 13.7x A- · PEG 0.59 A-
Why now. ADMA’s dominant position in the U.S. IVIG market, anchored by BIVIGAM and ASCENIV, fuels a high‑margin franchise that is already delivering 33% profit margin, 41.4% ROE and $116 m free cash flow. Coupled with a cheap P/E of 13.7 and a PEG of 0.59, the Bull Rankings model awards a Quality‑Growth score of 81.8, with Value as its strongest pillar, underscoring that the stock is fundamentally undervalued relative to its cash‑generating power. The thesis hinges on the continued compounding of IVIG earnings as the aging and immunodeficient patient base expands.
Moat. ADMA controls a proprietary plasma collection network that supplies the raw material for its IVIG products, creating a high switching cost for hospitals and insurers. This supply advantage, together with pricing power evident in a 33% margin and a 41.4% ROE, locks in cash flow and deters new entrants from replicating the scale‑intensive plasma sourcing model.
Risk. The company’s growth engine is modest, with only 8% revenue YoY growth while the Bull Rankings model’s reverse‑DCF assumes just 4% free‑cash‑flow growth for a decade, suggesting the market may already be pricing in optimistic cash‑flow expansion. A debt‑to‑equity of 1.11 adds leverage risk, and any disruption in plasma collection or a price‑cut war in the IVIG space could compress margins and invalidate the valuation premise. A sustained slowdown in IVIG demand would confirm the bear case.
Horizon. 1-3 yr $17.00 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
16. EPAM — EPAM Systems, Inc. · score 81.4
Information Technology Services · price $117.04 · 1Y $122.82 · 5Y $179.83 · 10Y $266.76
FCF $483m C · Rev +10.8% B · D/E 0.04 A- · P/E 15.9x A- · PEG 0.63 A-
Why now. EPAM’s digital platform engineering and cloud services are fueling a revenue growth of 10.8% YoY while delivering free cash flow of $483m and a modest PE of 15.9x, underscoring a cash‑rich, fairly‑priced growth engine. Our Bull Rankings model awards an 81.4/100 quality‑growth score, with Value as the strongest pillar, confirming the stock is undervalued relative to its cash generation and the buy‑back signal. The thesis hinges on the compounding of high‑margin platform engineering contracts that should keep growth above the 6% FCF growth baked into today’s price.
Moat. EPAM’s end‑to‑end engineering practice—from requirements analysis to smart automation—creates deep integration with enterprise customers, locking in multi‑year platform contracts that are costly to replace. The low debt‑to‑equity of 0.04 and a solid ROE of 11.4% stem from this sticky revenue base and efficient delivery model, giving EPAM a cost advantage that rivals can’t quickly replicate.
Risk. The stock’s beta of 1.38 makes it vulnerable to market swings, and a profit margin of only 7.2% leaves little cushion if pricing pressure or higher labor costs erode earnings. A slowdown in revenue growth below the current 10.8% would force the implied 6% FCF growth assumption to look overly optimistic, and a breach of the 52‑week low at $73.06 would trigger a sell‑off. Confirmation of the bear case would be a quarterly margin dip below 6% coupled with a revenue slowdown to single‑digit growth.
Horizon. 1-3 yr $122.82 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $179.83 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $266.76 if current growth sustains into durable earnings power.
17. DECK — Deckers Outdoor Corporation · score 80.8
Footwear & Accessories · price $85.81 · 1Y $122.81 · 5Y $179.81 · 10Y $266.73
FCF $1.1b C+ · Rev +7.9% B · D/E 0.21 A- · P/E 12.2x A- · PEG 1.05 B+
Why now. Deckers is poised to double down on its high‑margin HOKA performance‑shoe franchise, where the 44.1% ROE reflects pricing power in premium outdoor categories and the 7.9% YoY revenue growth shows the segment still expanding. Coupled with a 18.4% profit margin and a market cap of $11.7B, the company can fund aggressive buybacks while compounding earnings. The thesis hinges on HOKA’s continued capture of the fast‑growing trail‑running market, which should keep the growth engine humming.
Moat. Deckers’ moat lives in the HOKA and UGG platforms, which command premium pricing thanks to differentiated product tech and a loyal lifestyle following that competitors struggle to replicate quickly. The 44.1% ROE is driven by this pricing power and a distribution network that reaches both specialty outdoor retailers and mass‑market channels, locking in repeat demand and limiting substitution.
Risk. The stock trades at a modest PE of 12.2, but the Bull Rankings model’s reverse DCF implies a -3% annual free‑cash‑flow growth rate for the next decade, meaning the market is already pricing in a slowdown that would clash with the 7.9% revenue growth trend. A sustained dip in HOKA demand or a margin squeeze would push the price toward the 52‑week low of $78.91, confirming the bear case.
Horizon. 1-3 yr $122.81 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $179.81 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $266.73 if current growth sustains into durable earnings power.
18. PODD — Insulet Corporation · score 79.7
Medical Devices · price $147.48 · 1Y $171.91 · 5Y $251.69 · 10Y $373.37
FCF $294m C · Rev +29.4% A- · D/E 0.67 C+ · P/E 27.6x B · PEG 1.16 B+
Why now. The Omnipod 5 automated insulin delivery system is rapidly winning market share in the U.S. and abroad, and its Bluetooth‑linked AID algorithm drives a 29.4% YoY revenue growth while delivering a 12.3% profit margin and a robust ROE of 26.4%. Coupled with a free‑cash‑flow generation of $294 m and a PEG of 1.16, the business compounds earnings at a rate that comfortably exceeds the 27% FCF growth baked into today’s price, leaving upside for continued compounding. The thesis hinges on the Omnipod platform’s ability to lock in patients and providers, sustaining growth well beyond the next decade.
Moat. Insulet’s moat stems from the integrated Omnipod ecosystem – a pod, a proprietary AID algorithm, and a Bluetooth‑enabled manager that together create high switching costs for both diabetics and clinicians. The patented pod design and seamless CGM integration lock in reimbursement contracts, while the 26.4% ROE reflects pricing power derived from being the sole FDA‑cleared, tubeless, automated system in a growing insulin‑dependent population.
Risk. The biggest headwind is the looming competition from major med‑device giants launching their own tubeless AID systems, which could compress the current PE of 27.6x and stall the 29.4% revenue growth trajectory. A slowdown in adoption or a price war would erode the 12.3% margin and push the debt‑to‑equity ratio above the current 0.67, signaling financial strain. A sustained drop in quarterly revenue growth below 20% would confirm the bear case and invalidate the growth premium priced in today.
Horizon. 1-3 yr $171.91 (analyst consensus (n=22)) — fundamentals + valuation re-rating. 5 yr $251.69 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $373.37 if current growth sustains into durable earnings power.
19. RMD — ResMed Inc. · score 79.5
Medical Instruments & Supplies · price $228.35 · 1Y $246.13 · 5Y $360.35 · 10Y $534.56
FCF $1.6b C+ · Rev +9.9% B · D/E 0.13 B+ · P/E 21.9x B+ · PEG 1.33 B
Why now. ResMed’s AirView cloud platform, paired with its portable diagnostic devices like NightOwl and ApneaLink Air, is locking in a growing base of sleep clinics and home‑care patients, driving a virtuous compounding loop. The business is delivering 9.9% revenue growth YoY, 26.9% profit margin and $1.6 B of free cash flow while maintaining a razor‑thin 0.13 debt‑to‑equity ratio, giving it the cash to reinvest and return capital. The thesis rests on the relentless expansion of cloud‑connected sleep care, which should keep the growth engine humming for years to come.
Moat. AirView creates a data‑rich, subscription‑based ecosystem that clinicians cannot easily replace, because each patient’s longitudinal sleep data is tied to ResMed’s proprietary analytics and device firmware. This switching cost, combined with the company’s 23.1% ROE—derived from pricing power in the premium sleep‑apnea market—locks in high‑margin revenue and shields against new entrants.
Risk. The stock trades at a lofty 21.9× forward P/E despite a modest 9.9% revenue growth rate, and the Bull Rankings model’s reverse‑DCF implies only ~5% free‑cash‑flow growth for the next decade—well below the historical margin and growth profile, suggesting the market may be over‑optimistic. A slowdown in device adoption or a pull‑back in cloud subscription renewals would force the valuation down, and a breach of the implied growth assumption would confirm the bear case.
Horizon. 1-3 yr $246.13 (analyst consensus (n=16)) — fundamentals + valuation re-rating. 5 yr $360.35 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $534.56 if current growth sustains into durable earnings power.
20. CPAY — Corpay, Inc. · score 79.2
Software - Infrastructure · price $416.37 · 1Y $461.00 · 5Y $674.95 · 10Y $1,001
FCF $1.6b C+ · Rev +20.4% A- · D/E 2.75 D · P/E 25.3x B+ · PEG 0.80 A-
Why now. Corpay’s corporate payments platform is rapidly becoming the backbone of enterprise spend, driving a 20.4% YoY revenue growth while delivering a 22.7% profit margin and a stellar 32.2% ROE. The combination of cross‑border payments, virtual cards and AP modernization creates a self‑reinforcing spend‑management flywheel that will keep earnings compounding for years, making the current price a premium for that growth.
Moat. The moat lies in Corpay’s integrated corporate‑payment suite that locks large enterprises into a single spend‑management workflow, creating high switching costs and enabling pricing power that fuels its 32.2% ROE. Virtual card issuance and AP automation lock in recurring transaction fees that competitors can’t replicate quickly without massive integration effort.
Risk. The stock trades at a forward‑PE of 25.3× on a growth rate that the Bull Rankings model’s reverse‑DCF assumes only 3% annual FCF growth, a stark mismatch to the 20.4% revenue expansion and suggesting the market may be over‑optimistic; coupled with a debt‑to‑equity of 2.75, any slowdown in spend could force leverage higher and pressure the valuation. A breach of the 3% implied growth assumption would trigger a sharp re‑rating.
Horizon. 1-3 yr $461.00 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $674.95 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $1,001 if current growth sustains into durable earnings power.
21. DXCM — DexCom, Inc. · score 79
Medical Devices · price $87.90 · 1Y $94.12 · 5Y $137.80 · 10Y $204.42
FCF $1.4b C+ · Rev +15.5% B+ · D/E 0.53 B · P/E 34.7x C+ · PEG 1.35 B
Why now. Medical Devices · market cap $33.2b. 5% off the 52-week high of $92.59. Revenue growing +16%, comfortably above the S&P median. 25 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $94.12 (implying +7% upside).
Moat. Net margin 20% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 38% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Beta 1.42 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 35x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $94.12 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $137.80 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $204.42 if current growth sustains into durable earnings power.
22. YUMC — Yum China Holdings, Inc. · score 78.5
Restaurants · price $43.60 · 1Y $62.05 · 5Y $90.85 · 10Y $134.77
FCF $940m C+ · Rev +8.8% B · D/E 0.38 A- · P/E 16.0x B+ · PEG 0.97 B+
Why now. Yum China’s KFC franchise continues to out‑drive earnings, delivering 8.8% YoY revenue growth, a solid 7.8% profit margin and $940 m of free cash flow in the latest twelve months. Our Bull Rankings model awards the business a Quality‑growth score of 78.5, with Quality (85) as the strongest pillar, underscoring the durability of its operating model, while Value (75) is the weakest, suggesting the market is already pricing in optimism. The reverse‑DCF shows the current $43.60 price assumes only ~5% FCF growth, well below the 8.8% revenue pace, meaning the stock is undervalued relative to its real growth engine. The thesis rests on KFC’s unrivaled footprint in China’s fast‑food market continuing to compound cash flow.
Moat. Yum China’s moat comes from its massive, franchised KFC and Pizza Hut restaurant network that couples in‑store traffic with a proprietary online delivery platform, locking in repeat spend from urban diners. The 18.2% ROE reflects pricing power derived from category leadership in quick‑service Chinese cuisine, a lever competitors can’t replicate quickly without comparable scale and supply‑chain depth.
Risk. The bear case hinges on a slowdown in the 8.8% revenue growth trajectory as Chinese consumer spending tightens and local fast‑food rivals intensify price wars, compressing the already modest 7.8% margin. At a forward P/E of 16, the market may be overpaying for a growth rate that could dip below the 5% FCF growth baked into the price; a miss on quarterly revenue or margin would trigger a sell‑off toward the 52‑week low of $40.15, confirming the downside.
Horizon. 1-3 yr $62.05 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $90.85 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $134.77 if current growth sustains into durable earnings power.
23. META — Meta Platforms, Inc. · score 77.7
Internet Content & Information · price $616.77 · 1Y $754.77 · 5Y $1,105 · 10Y $1,639
FCF $41.0b A · Rev +27.7% A- · D/E 0.43 B+ · P/E 23.3x B · PEG 0.82 B+
Why now. Meta’s unstoppable network effect in the Family of Apps fuels a compounding revenue engine – the FoA segment’s 27.7% YoY revenue growth is backed by a 29.8% profit margin and a staggering $41.0B free‑cash‑flow, delivering a 10‑year implied FCF growth of ~33% in our reverse‑DCF. Our Bull Rankings model gives Meta a Quality‑Growth score of 77.7, with Growth as the strongest pillar (92) and Value the weakest (59), underscoring that the business’s earnings power, not cheapness, drives the thesis. The whole case rests on the FoA’s ability to keep users and advertisers locked in, letting the high‑margin cash machine keep compounding.
Moat. The moat lives in the entrenched social graph across Facebook, Instagram and Messenger – a combined user base that creates a lock‑in loop of content, community and commerce. This network generates pricing power, evident in a ROE of 26.1%, because advertisers pay a premium to reach billions of engaged users that competitors cannot replicate quickly. Reality Labs adds a nascent but defensible hardware foothold, but the real defensive wall is the data‑rich, cross‑platform ecosystem that makes switching costly for both users and brands.
Risk. The bear case hinges on the valuation premium: a forward P/E of 23.3 is high for a growth name, and the reverse‑DCF’s 33% FCF growth assumption outpaces the already strong 27.7% revenue growth, leaving little margin for a slowdown. A beta of 1.24 amplifies market volatility, and any head‑wind to ad spend or a misstep in Reality Labs could compress margins, snapping the 29.8% profit margin. A sustained drop in ad revenue below expectations would validate the over‑optimistic pricing and trigger a sell‑off.
Horizon. 1-3 yr $754.77 (analyst consensus (n=57)) — fundamentals + valuation re-rating. 5 yr $1,105 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $1,639 if current growth sustains into durable earnings power.
24. CI — The Cigna Group · score 76.9
Healthcare Plans · price $282.52 · 1Y $341.42 · 5Y $499.87 · 10Y $741.52
FCF $9.1b B+ · Rev +11.3% B · D/E 0.74 C+ · P/E 11.7x A · PEG 0.77 A-
Why now. Cigna’s Evernorth Pharmacy Benefit Services is the engine driving an 11.3% YoY revenue growth while delivering a massive $9.1B of free cash flow and a rock‑bottom PE of 11.7x, making the stock a cash‑rich growth story at a discount. The Bull Rankings model rates CI at a 76.9 quality‑growth score, with Value as its strongest pillar, underscoring that the market is already rewarding the business’s cash generation. The thesis rests on the compounding power of Evernorth’s integrated PBM platform, which should keep the free‑cash‑flow engine humming for years to come.
Moat. Evernorth’s pharmacy‑benefit‑management network locks in large employer and health‑plan contracts, creating high switching costs and a data‑rich platform that rivals can’t replicate quickly. This scale translates into a solid ROE of 16.8%, generated by pricing leverage in drug‑benefit design and specialty pharmacy distribution. The low‑beta (0.32) profile further reflects the defensive, subscription‑style cash flows that protect the moat.
Risk. The Bull Rankings model flags Quality as CI’s weakest pillar, and the company’s razor‑thin 2.3% profit margin leaves little room for error if drug‑price pressures intensify or regulatory changes bite. A debt‑to‑equity of 0.74 adds leverage risk, and the reverse‑DCF shows the current price implies a -11% annual free‑cash‑flow growth rate—far below the 11.3% revenue growth, suggesting the market may be over‑optimistic. A sustained margin compression or a spike in debt servicing would confirm the bear case and topple the upside.
Horizon. 1-3 yr $341.42 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $499.87 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $741.52 if current growth sustains into durable earnings power.
25. WMG — Warner Music Group Corp. · score 76.9
Entertainment · price $28.78 · 1Y $36.88 · 5Y $54.00 · 10Y $80.10
FCF $836m C+ · Rev +12.9% B+ · D/E 4.53 D · P/E 23.0x B · PEG 0.52 A-
Why now. Warner Music’s explosive 12.9% FY revenue growth 12.9% and a staggering ROE of 78.7% prove its catalog licensing engine compounds earnings, while a PEG of 0.52 signals the market is underpricing that growth; the bull case hinges on the Recorded Music segment’s streaming surge continuing to fuel free cash flow of $836 m and drive the stock toward the consensus 1‑yr target of $36.88.
Moat. The company’s moat lives in its two‑million‑song publishing catalog and the exclusive rights it licenses to streaming platforms and advertisers, creating a high‑margin, repeatable revenue stream that fuels the 78.7% ROE by giving Warner pricing power over content owners and limiting rivals’ ability to duplicate its IP base.
Risk. Bears point to a leveraged balance sheet with a debt‑to‑equity of 4.53 and a beta of 1.3, suggesting volatility and higher financing risk, while a P/E of 23 may already price in optimistic growth; a slip in streaming royalties or a credit downgrade would validate the risk and crush the upside.
Horizon. 1-3 yr $36.88 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $54.00 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $80.10 if current growth sustains into durable earnings power.
26. VRT — Vertiv Holdings Co · score 76
Electrical Equipment & Parts · price $280.53 · 1Y $338.15 · 5Y $495.09 · 10Y $734.43
FCF $2.9b B · Rev +26.2% A- · D/E 0.70 B · P/E 63.3x D · PEG 0.95 B+
Why now. Vertiv’s dominance in critical data‑center power and thermal management fuels a compounding revenue engine – its 26.2% FY YoY revenue growth is underpinned by soaring demand for AC/DC power modules and liquid‑cooled thermal solutions across hyperscale operators. The business converts that growth into high returns, evident in a 15.1% profit margin and a stellar ROE of 36.4%, while our Bull Rankings model flags a Quality‑Growth score of 76 (Growth pillar 91) as the strongest driver. The thesis rests on the persistence of data‑center expansion, which should keep free‑cash‑flow compounding at double‑digit rates for the foreseeable future.
Moat. Vertiv’s moat lies in its end‑to‑end infrastructure suite – from single‑phase UPS to integrated modular racks – that locks in large‑scale customers who require tightly engineered, service‑backed solutions for mission‑critical uptime. This high‑touch, lifecycle service model creates switching costs that protect pricing power, reflected in the company’s 36.4% ROE, which stems from premium pricing on its proprietary power‑management and liquid‑cooling technologies that rivals cannot replicate quickly.
Risk. The bear case centers on the lofty valuation: a forward P/E of 63.3 implies the market is pricing in near‑term growth far beyond the historical 26% revenue expansion, and the beta of 2.08 magnifies any macro‑tech slowdown. A pullback in data‑center capex or a shift to cheaper, commodity‑grade power solutions would compress margins and expose the high debt‑to‑equity ratio of 0.7, potentially forcing deleveraging at the expense of growth. The key red flag would be a sustained revenue growth dip below 15% YoY, which would invalidate the reverse‑DCF implied 44% FCF growth assumption.
Horizon. 1-3 yr $338.15 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $495.09 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $734.43 if current growth sustains into durable earnings power.
27. MELI — MercadoLibre, Inc. · score 75.8
Internet Retail · price $1978.36 · 1Y $2,265 · 5Y $3,316 · 10Y $4,919
FCF $12.4b A- · Rev +41.2% A · D/E 1.69 C+ · P/E 53.8x D · PEG 0.96 B+
Why now. The bull case hinges on MercadoLibre’s dominant Mercado Pago ecosystem in Brazil and Mexico, where the fintech platform now processes $12.4B of free cash flow and fuels a 41.2% YoY revenue surge while the company enjoys a 7.6% profit margin. This high‑velocity growth, powered by the network of merchants and consumers on its marketplace, compounds earnings at a rate that far outpaces the modest −6%/yr free‑cash‑flow growth implied by the reverse DCF, leaving ample upside. The thesis rests on the continued expansion of digital payments and credit within its ecosystem.
Moat. MercadoLibre’s moat stems from the integrated Mercado Pago and Mercado Crédito stack, which locks merchants into a single‑tap payment and financing solution, creating sticky cash‑flow and high cross‑sell rates. The resulting ROE of 23.8% reflects pricing power and cost efficiencies that rivals cannot replicate without building a comparable user base and credit infrastructure.
Risk. The bear case centers on the elevated valuation— a forward P/E of 53.8—which assumes sustained double‑digit growth; any slowdown in revenue growth or margin compression would expose the stock to a sharp correction. A rising debt‑to‑equity ratio of 1.69 adds financial leverage risk, and a beta of 1.31 amplifies downside in a market pullback. A breach of the 52‑week low at $1,495 would confirm the overvaluation narrative.
Horizon. 1-3 yr $2,265 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,316 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $4,919 if current growth sustains into durable earnings power.
28. EME — EMCOR Group, Inc. · score 75.7
Engineering & Construction · price $754.16 · 1Y $1,033 · 5Y $1,513 · 10Y $2,244
FCF $1.2b C+ · Rev +18.9% B+ · D/E 0.13 A- · P/E 23.5x B+ · PEG 0.31 A
Why now. EMCOR’s integrated power‑generation and HVAC construction franchise is set to compound on the 18.9% FY revenue growth, the 35.3% ROE and a robust $1.2 B free‑cash‑flow run‑rate, all while sitting on a low 0.13 debt‑to‑equity balance sheet; this engine of cash generation fuels the 22% FCF‑growth assumption baked into today’s price, making the upside hinge on sustaining the high‑growth, high‑margin contracts in the U.S. and U.K. power‑systems market.
Moat. The moat lives in EMCOR’s end‑to‑end services for power transmission, distribution and generation—design, integration, startup and long‑term maintenance—creating multi‑year, high‑switching‑cost contracts with utilities and industrial customers that lock in recurring revenue and justify the 35% ROE through pricing power and economies of scale.
Risk. The bear case centers on the market pricing a 23.5× forward P/E for a company whose revenue growth may decelerate below the 22% FCF‑growth implied by the reverse DCF, especially if utility spending cycles soften; a slip in margin or a rise in debt would push the valuation into over‑extension, and a beta of 1.13 signals heightened sensitivity to broader economic swings. Confirmation would be a quarterly earnings miss that forces the P/E below 20× and erodes the growth premium.
Horizon. 1-3 yr $1,033 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $1,513 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $2,244 if current growth sustains into durable earnings power.
29. STRL — Sterling Infrastructure, Inc. · score 75.6
Engineering & Construction · price $486.49 · 1Y $876.00 · 5Y $1,283 · 10Y $1,903
FCF $482m C · Rev +60.8% A · D/E 0.24 A- · P/E 35.1x C+ · PEG 0.60 A-
Why now. Sterling Infrastructure’s explosive 60.8% FY revenue growth is powered by its E‑Infrastructure Solutions segment, which is winning multi‑year build‑outs for e‑commerce distribution centers and data centers – the backbone of the digital economy. Coupled with a razor‑thin PE of 35.1 and a massive $482 m of free cash flow, the stock is primed to compound earnings as the same customers expand capacity for years to come; the thesis hinges on sustaining this high‑growth pipeline.
Moat. The moat lives in STRL’s deep relationships with blue‑chip e‑commerce and data‑center operators who lock in long‑term site‑development contracts, creating switching costs that rivals can’t match without years of permitting expertise. This pricing power fuels a stellar ROE of 31.8%, reflecting the ability to earn outsized returns on capital deployed in these high‑margin, specialist projects.
Risk. The biggest headwind is the lofty valuation: a PE of 35.1 and a beta of 1.85 imply the market is pricing in near‑term growth that may be hard to sustain if e‑commerce capex cycles slow or infrastructure funding tightens, which would compress margins and push the PE toward sector norms. A sustained slowdown in the E‑Infrastructure pipeline would trigger a sharp re‑rating.
Horizon. 1-3 yr $876.00 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $1,283 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $1,903 if current growth sustains into durable earnings power.
30. CCK — Crown Holdings, Inc. · score 75.3
Packaging & Containers · price $115.16 · 1Y $136.57 · 5Y $199.95 · 10Y $296.62
FCF $1.2b C+ · Rev +10.3% B · D/E 1.86 C+ · P/E 16.5x B+ · PEG 0.64 A-
Why now. Crown’s moat in recyclable aluminum beverage cans fuels a compounding revenue engine – the Americas Beverage segment is expanding at 10.3% YoY, backed by a rock‑solid 27.3% ROE and $1.2B of free cash flow that fuels buybacks and a dividend hike. With a PEG of 0.64 and a P/E of 16.5, the market is already rewarding the growth story, but the real catalyst is the continued shift to sustainable packaging that will keep earnings compounding. The thesis rests on the persistence of that beverage‑can demand surge.
Moat. The company’s pricing power stems from its dominant position supplying aluminum cans to major beverage brands across the Americas, Europe and Asia‑Pacific, creating high switching costs and long‑term contracts. This scale translates into a ROE of 27.3%, driven by efficient plant utilization and low‑cost aluminum sourcing that competitors cannot replicate quickly.
Risk. Leverage is a red flag – a debt‑to‑equity of 1.86 sits well above the sector norm, and the reverse DCF shows the current price assumes a -14% annual free‑cash‑flow decline, far below the actual 10.3% revenue growth. If margin pressure deepens or cash flow turns negative, the high leverage could force dividend cuts and halt buybacks, crushing the bull case.
Horizon. 1-3 yr $136.57 (analyst consensus (n=14)) — fundamentals + valuation re-rating. 5 yr $199.95 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $296.62 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.